Consolidated Statements of Cash Flows - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating Activities
Net income before allocation to noncontrolling interests		$ 22,025	$ 9,195	$ 16,056
Discontinued operations––net of tax		(434)	2,529	5,318
Net income from continuing operations before allocation to noncontrolling interests		22,459	6,666	10,738
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization		5,191	4,681	5,755
Asset write-offs and impairments		276	2,049	2,889
TCJA impact		0	0	(323)
Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed	[1]	0	(6)	(8,254)
Deferred taxes from continuing operations		(4,293)	(1,575)	561
Share-based compensation expense		1,182	755	687
Benefit plan contributions in excess of expense/income		(3,123)	(1,242)	(55)
Other adjustments, net		(1,573)	(479)	(1,080)
Other changes in assets and liabilities, net of acquisitions and divestitures:
Trade accounts receivable		(3,811)	(1,275)	(1,124)
Inventories		(1,125)	(778)	(1,071)
Other assets		(1,057)	(137)	847
Trade accounts payable		1,242	355	(341)
Other liabilities		18,721	2,768	861
Other tax accounts, net		(1,166)	(1,240)	(3,074)
Net cash provided by operating activities from continuing operations		32,922	10,540	7,015
Net cash provided by/(used in) operating activities from discontinued operations		(343)	3,863	5,572
Net cash provided by operating activities		32,580	14,403	12,588
Investing Activities
Purchases of property, plant and equipment		(2,711)	(2,226)	(2,046)
Purchases of short-term investments		(38,457)	(13,805)	(6,835)
Proceeds from redemptions/sales of short-term investments		27,447	11,087	9,183
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less		(8,088)	920	6,925
Purchases of long-term investments		(1,068)	(597)	(201)
Proceeds from redemptions/sales of long-term investments		649	723	232
Acquisitions of businesses, net of cash acquired		0	0	(10,861)
Other investing activities, net	[1]	(305)	(265)	(223)
Net cash provided by/(used in) investing activities from continuing operations		(22,534)	(4,162)	(3,825)
Net cash provided by/(used in) investing activities from discontinued operations		(12)	(109)	(120)
Net cash provided by/(used in) investing activities		(22,546)	(4,271)	(3,945)
Financing Activities
Proceeds from short-term borrowings		0	12,352	16,455
Principal payments on short-term borrowings		0	(22,197)	(8,378)
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less		(96)	(4,129)	2,551
Proceeds from issuance of long-term debt		997	5,222	4,942
Principal payments on long-term debt		(2,004)	(4,003)	(6,806)
Purchases of common stock		0	0	(8,865)
Cash dividends paid		(8,729)	(8,440)	(8,043)
Other financing activities, net		16	(444)	(342)
Net cash provided by/(used in) financing activities from continuing operations		(9,816)	(21,640)	(8,485)
Net cash provided by/(used in) financing activities from discontinued operations		0	11,991	0
Net cash provided by/(used in) financing activities		(9,816)	(9,649)	(8,485)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents		(59)	(8)	(32)
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents		159	475	125
Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period		1,825	1,350	1,225
Cash and cash equivalents and restricted cash and cash equivalents, at end of period		1,983	1,825	1,350
Cash paid/(received) during the period for:
Income taxes		7,427	3,153	3,664
Interest paid		1,467	1,641	1,587
Interest rate hedges		(2)	(20)	(42)
Non-cash transactions:
Right-of-use assets obtained in exchange for lease liabilities		1,943	410	314
Consumer Healthcare JV [Member]
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed				(8,300)
Non-cash transactions:
Equity investment in exchange for Pfizer's assets	[1]	$ 0	$ 0	$ 15,711

[1] The $8.3 billion Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed reflects the receipt of a 32% equity-method investment in the new company initially valued at $15.7 billion in exchange for net assets contributed of $7.6 billion and is presented in operating activities net of $146 million cash conveyed that is reflected in Other investing activities, net. See Note 2C.